Alder BioPharma (ALDR): EPO Decision Only Impacts Valuation By $1-$2 - BMO

November 22, 2016 8:09 AM EST
Get Alerts ALDR Hot Sheet
Price: $21.00 -2.55%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade ALDR Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

BMO Capital analyst, Matthew Luchini, reiterated his Outperform rating on shares of Alder Biopharm (NASDAQ: ALDR) despite shares being under pressure following the European Patent Office's (EPO) oral decision, which revoked Teva's patent claims related to CGRP antagonist antibodies for the treatment of migraine but maintained and narrowed method of use claims.

The analyst expects Alder to appeal the decision but the analyst believes there the impact of a 5%-10% royalty on EU sales during the patent period (expires 2026) would result in only a $1-$2 impact on valuation.

No change to the price target of $42.

For an analyst ratings summary and ratings history on Alder Biopharm click here. For more ratings news on Alder Biopharm click here.

Shares of Alder Biopharm closed at $26.45 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

BMO Capital

Add Your Comment